Amneal Pharmaceuticals (AMRX) EBITDA Margin (2017 - 2026)

Amneal Pharmaceuticals has reported EBITDA Margin for 10 years, with the latest figure at 16.3% in Q2 2026.

• On a quarterly basis, EBITDA Margin rose 93.0% year-over-year to 16.3% in Q2 2026; TTM through Jun 2026 was 14.56%, a 137.0% increase from a year earlier, with the FY2025 full-year figure at 13.05%, up 413.0% from the prior year.
• EBITDA Margin was 16.3% for Q2 2026 at Amneal Pharmaceuticals, down from 19.62% in the prior quarter.
• The five-year high for EBITDA Margin was 19.62% in Q1 2026, with the low at 35.51% in Q2 2022.
• Average EBITDA Margin over 5 years is 7.82%, with a median of 11.29% recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin plunged 4805 bps in 2022, then jumped 4888 bps in 2023.
• Over 5 years, EBITDA Margin stood at 5.91% in 2022, then sank by 61 bps to 2.3% in 2023, then jumped by 351 bps to 10.38% in 2024, then surged by 33 bps to 13.76% in 2025, then advanced by 18 bps to 16.3% in 2026.
• The last three EBITDA Margin figures came in at 16.3% (Q2 2026), 19.62% (Q1 2026), and 13.76% (Q4 2025), per Business Quant data.